Abstract:Journal of Psychopharmacology, Ahead of Print. Background:Selective serotonin reuptake inhibitors (SSRIs) are used for the treatment of several conditions including anxiety disorders, but the basic neurobiology of serotonin function remains unclear. The amygdala and prefrontal cortex are strongly innervated by serotonergic projections and have been suggested to play an important role in anxiety expression. However, serotonergic function in behaviour and SSRI-mediated neurobiological changes remain incompletely understood.Aims:To investigate the neural correlates of subchronic antidepressant administration.Methods:We investigated whether the 2- to 3-week administration of a highly selective SSRI (escitalopram) would alter brain activation on a task robustly shown to recruit the bilateral amygdala and frontal cortices in a large healthy volunteer sample. Participants performed the task during a functional magnetic resonance imaging acquisition before (n = 96) and after subchronic escitalopram (n = 46, days of administration mean (SD) = 15.7 (2.70)) or placebo (n = 40 days of administration mean (SD) = 16.2 (2.90)) self-administration.Results:Compared to placebo, we found an elevation in right amygdala activation to the task after escitalopram administration without significant changes in mood. This effect was not seen in the left amygdala, the dorsomedial region of interest, the subgenual anterior cingulate cortex or the right fusiform area. There were no significant changes in connectivity between the dorsomedial cortex and amygdala or the subgenual anterior cingulate cortex after escitalopram administration.Conclusions:To date, this most highly powered study of subchronic SSRI administration indicates that, contrary to effects often seen in patients with anxiety disorders, subchronic SSRI treatment may increase amygdala activation in healthy controls. This finding highlights important gaps in our understanding of the functional role of serotonin.

Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model

Escitalopram attenuates β-amyloid-induced tau hyperphosphorylation in primary hippocampal neurons through the 5-HT1A receptor mediated Akt/GSK-3β pathway.

Escitalopram Alleviates Alzheimer's Disease-Type Tau Pathologies in the Aged P301L Tau Transgenic Mice.

Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial

Effect of short-term escitalopram treatment on neural activation during emotional processing

Citalopram Restores Short-Term Memory Deficit and Non-Cognitive Behaviors in APP/PS1 Mice While Halting the Advance of Alzheimer's Disease-Like Pathology

Amygdala activity after subchronic escitalopram administration in healthy volunteers: A pharmaco-functional magnetic resonance imaging study

Escitalopram Alleviates Stress-Induced Alzheimer's Disease-Like Tau Pathologies and Cognitive Deficits by Reducing Hypothalamic-Pituitary-adrenal Axis Reactivity and Insulin/gsk-3Β Signal Pathway Activity.

Modulation of serotonin transporter expression by escitalopram under inflammation

Antidepressant sertraline increases thioflavin-S and Congo red deposition in APPswe/PSEN1dE9 transgenic mice

Chronic Escitalopram in Healthy Volunteers Has Specific Effects on Reinforcement Sensitivity: a Double-Blind, Placebo-Controlled Semi-Randomised Study

Effects of Escitalopram, R-citalopram, and Reboxetine on Serum Levels of Tumor Necrosis Factor-Α, Interleukin-10, and Depression-Like Behavior in Mice after Lipopolysaccharide Administration

Escitalopram moderately outperforms citalopram towards anti-neuroinflammation and neuroprotection in 6-hydroxydopamine-induced mouse model of Parkinson's disease

Pilot Study of the Reducing Effect on Amyloidosis in Vivo by Three FDA Pre-Approved Drugs Via the Alzheimer's APP 5' Untranslated Region.

Protective Effects of Long-Term Escitalopram Administration on Memory and Hippocampal BDNF and BCL-2 Gene Expressions in Rats Exposed to Predictable and Unpredictable Chronic Mild Stress

Escitalopram Targets Oxidative Stress, Caspase-3, BDNF and MeCP2 in the Hippocampus and Frontal Cortex of a Rat Model of Depression Induced by Chronic Unpredictable Mild Stress

Escitalopram Ameliorates Tau Hyperphosphorylation and Spatial Memory Deficits Induced by Protein Kinase A Activation in Sprague Dawley Rats

The Role of Fluoxetine in Activating Wnt/β-Catenin Signaling and Repressing β-Amyloid Production in an Alzheimer Mouse Model

Fluoxetine attenuates the impairment of spatial learning ability and prevents neuron loss in middle-aged APPswe/PSEN1dE9 double transgenic Alzheimer's disease mice

The Effect and Molecular Mechanisms of SB239063 on Regulating Aβ Generation in APPswe/PS1dE9 Mice

Effect of selective serotonin reuptake inhibitors on expression of 5-HT1AR and neurotransmitters in rats with vascular dementia